Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer

National Taiwan University Hospital40 enrolled

Overview

The primary objective of this study is to find out the response rate of twice weekly paclitaxel and cisplatin and weekly HDFL in recurrent or metastatic esophageal carcinoma patients who need palliative Chemotherapy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Esophageal Cancer

Interventions

Paclitaxel,Cisplatin,5-Fu,Folic AcidDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pathologically proven esophageal squamous cell or adenocarcinoma Recurrence or metastasis Measurable disease (\> 1 X 1 cm) by CXR, CT scan or MRI,Age \> 18, KPS \> 60% , Cre \< 1.5mg/dl, AST/ALT \< 3.5 X N, Bil \< 2.0mg/dl WBC \> 4,000/mm3, ANC \> 2,000/ mm3, Plt \> 100,000/mm3 Exclusion Criteria: * Prior chemo (except as radiosensitizers)Recurrent, treated esophageal lesion only (except \> 2 months)

Locations (1)

Department of Oncology, National Taiwan University Hospital

Taipei, Taiwan

Outcomes

Primary Outcomes

Response rate

Secondary Outcomes

Overall survival

Progression-free survival

Toxicity

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.